Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 19:9:5.
doi: 10.21037/sci-2022-031. eCollection 2022.

Eph receptor B2 (EPHB2) regulates cancer stem cell-like properties in hepatocellular carcinoma

Jhin Jieh Lim  1 , Edward Kai-Hua Chow  1   2   3 , Tan Boon Toh  2   3
Affiliations
Editorial

Eph receptor B2 (EPHB2) regulates cancer stem cell-like properties in hepatocellular carcinoma

Jhin Jieh Lim et al. Stem Cell Investig. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://sci.amegroups.com/article/view/10.21037/sci-2022-031/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
EPHB2 promotes CSC properties in HCC via Wnt/β-catenin signaling. (Left panel) EPHB2 tyrosine kinase receptor binds and activates SRC, activating a downstream AKT/GSK3β/β-catenin signaling axis. Activated β-catenin then enters the nucleus and forms a complex with TCF1 to induce transcription of EPHB2, resulting in a positive feedback loop. (Right panel) Inhibition of EPHB2 can be achieved using peptide antagonists to interfere with receptor-ligand binding, small molecule inhibitors of EPHB2 kinase activity, or the use of antibody-drug conjugates to specifically deliver cytotoxic therapies to tumor cells that overexpress EPHB2. EPHB2, Eph receptor B2; SRC, proto-oncogene tyrosine-protein kinase Src; AKT, protein kinase B; GSK3β, glycogen synthase kinase-3 beta; TCF1, T-cell-specific transcription factor 1; CSC, cancer stem cell; HCC, hepatocellular carcinoma.
See this image and copyright information in PMC

Comment on

References

    1. Wang T, Narayanaswamy R, Ren H, et al. Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. Cancer Biol Ther 2016;17:698-707. 10.1080/15384047.2016.1190488 - DOI - PMC - PubMed
    1. Hu S, Fu W, Li T, et al. Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci Transl Med 2017;9:eaag0339. 10.1126/scitranslmed.aag0339 - DOI - PubMed
    1. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-24. 10.1053/j.gastro.2008.12.004 - DOI - PMC - PubMed
    1. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-66. 10.1016/j.ccr.2008.01.013 - DOI - PubMed
    1. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010;120:3326-39. 10.1172/JCI42550 - DOI - PMC - PubMed